|
|
|
Real Estate News Releases
|
(CHARTPOPPERS.COM, February 03, 2010 ) The Consolidated Investment Analysis on Pfizer Inc. (NYSE:PFE) will be in particular interest to other competing companys within in its sector, such as Bristol Myers Squibb Co. (NYSE:BMY), Merck & Co. Inc. (NYSE: MRK) and Johnson & Johnson. (NYSE: JNJ)
Point Roberts, WA - Chartpoppers.com announces an investment report featuring company Pfizer Inc. (NYSE:PFE)
Pfizer Inc. is a research-based, global pharmaceutical company. The Company discovers, develops, manufactures and markets prescription medicines for humans and animals. It operates in two business segments: Pharmaceutical and Animal Health. Pfizer also operates several other businesses, including the manufacture of gelatin capsules, contract manufacturing and bulk pharmaceutical chemicals
Recent News on Pfizer Inc. (NYSE:PFE)
Drug developer Pfizer Inc. said Monday European regulators approved an intravenous version of its high blood pressure drug Revatio.
The drug was already sold in Europe as a tablet for a specific type of high blood pressure called pulmonary arterial hypertension, which affects arteries in the lungs. Also, the Food and Drug Administration approved the tablet version in 2005 and the intravenous version in November.
Specifically, the European Commission has now approved the intravenous version for patients now prescribed oral Revatio and temporarily unable to take oral medicine but otherwise clinically stable.
Pulmonary arterial hypertension affects about 100,000 people worldwide, while hypertension in general affects more than a billion.
Shares of Pfizer rose 58 cents, or 3.2 percent, to $18.77 in afternoon trading. The stock has traded between $11.62 and $18.99 over the last 52 weeks.
To view the Consolidated Investment Analysis on Pfizer Inc. (NYSE:PFE) Please visit the stock pulse page at www.chartpoppers.com
In the report chartpoppers.com covers a recent Financial Summary, Analyst Consensus, Technical Analysis, Comparative Analysis and Insider Trading Activity.
The full report is available at www.chartpoppers.com
The U.S. Food and Drug Administration said on Tuesday it has approved Xiaflex, developed by Auxilium Pharmaceuticals Inc (AUXL.O), for treating a progressive hand disease known as Dupuytren's contracture.
The approval news sent shares of the small biotechnology company up nearly 9 percent.
The condition, which can affect a person's ability to straighten and properly use their fingers, is currently treated with surgery.
Xiaflex works by breaking down the excessive buildup of collagen in the hand.
"Since there are no other nonsurgical alternatives for Dupuytren's contracture, Xiaflex will be an important advance in the management of this disabling condition," Dr. Bob Rappaport, director of the anesthesiology, analgesia, and rheumatology division at the FDA's drug evaluation and research center, said in a statement.
The most common side effects seen in patients treated with the injected drug were fluid build up, swelling, bleeding, and pain in the injected area, the FDA said.
Auxilium and European partner Pfizer Inc (PFE.N) are also studying Xiaflex as a treatment for Peyronie's disease, in which a hard lump forms within the penis, reducing flexibility, thus causing pain and forcing the penis to bend or arc during erection.
Chartpoppers.com is a market research and investment commentary provider. Chartpoppers.com aims to bring undervalued, up and coming companies into the sight of both experienced and non-experienced investors. We try to help investors, at whatever stage in their careers, to get a grasp on the necessary financial data that they need in order to make a educated investment decision. From our daily trading ideas to a in depth coverage of whatÂ’s going on in the markets, we are sure that chartpoppers.com is exactly what you need in order succeed.
For More information please visit us at www.chartpoppers.com
Chartpoppers.com Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. ChartPoppers.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
CHARTPOPPERS.COM
Paul Marek
6047245332
info@chartpoppers.com 
|
|
|
|
Real Estate News by Sector
|
|
|
|
|
